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Abstract 
Objectives: Fluctuating endogenous and exogenous ovarian hormones may influence exercise 
parameters; yet control and verification of ovarian hormone status is rarely reported and limits current 
exercise science and sports medicine research. The purpose of this study was to determine the 
effectiveness of an individualised three-step method in identifying the mid-luteal or high hormone phase 
in endogenous and exogenous hormone cycles in recreationally-active women and determine hormone 
and demographic characteristics associated with unsuccessful classification. 
Design: Cross-sectional study design.  
Methods: Fifty-four recreationally-active women who were either long-term oral contraceptive users 
(n=28) or experiencing regular natural menstrual cycles (n=26) completed step-wise menstrual 
mapping, urinary ovulation prediction testing and venous blood sampling for serum/plasma hormone 
analysis on two days, six to 12 days after positive ovulation prediction to verify ovarian hormone 
concentrations.   
Results: Mid-luteal phase was successfully verified in 100% of oral contraceptive users, and 70% of 
naturally-menstruating women. Thirty percent of participants were classified as luteal phase deficient; 
when excluded, the success of the method was 89%. Lower age, body fat and longer menstrual cycles 
were significantly associated with luteal phase deficiency.  
Conclusions: A step-wise method including menstrual cycle mapping, urinary ovulation prediction and 
serum/plasma hormone measurement was effective at verifying ovarian hormone status. Additional 
consideration of age, body fat and cycle length enhanced identification of luteal phase deficiency in 
physically-active women. These findings enable the development of stricter exclusion criteria for 
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female participants in research studies and minimise the influence of ovarian hormone variations within 
sports and exercise science and medicine research.  
Key words  
ovarian hormones; menstruation; luteal phase; anovulation; contraceptive agents; menstrual 
disturbances   
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1. Introduction  
Fluctuations in endogenous oestrogen and progesterone throughout the menstrual cycle, and in 
exogenous hormones such as those present in oral contraceptives (OC), may influence exercise 
performance1. Furthermore, hormone status in physically-active women is highly individual and 
commonly influenced by OC use, anovulation, luteal phase deficiency, or menstrual disturbances such 
as amenorrhoea. Indeed, research investigating the influence of hormone status on exercise performance 
in women has yielded inconsistent data; this, at least in part, can be attributed to poor control and/or 
verification of menstrual cycle phase2.    
Early-follicular menstrual phase is simply identified by the onset of menstruation, and does not provide 
insight into luteal function and high ovarian hormone conditions, therefore the present method focuses 
on mid-luteal menstrual phase. Direct methods for identifying mid-luteal menstrual phase, such as 
ultrasound of follicular development and endometrial biopsies3,4, combined with frequent measures of 
serum/plasma ovarian hormone concentrations are time-consuming, costly and invasive. In applied 
exercise science and sports medicine research, indirect methods of menstrual cycle verification and/or 
control have been employed, including calendar cycle tracking5, basal body temperature fluctuations6, 
and use of ovulation prediction tests7. In isolation, these methods have low success and significant 
limitations, especially within physically-active women, who are at higher risk of experiencing 
anovulation or luteal phase deficiency8,9. Furthermore, without specifically measuring circulating 
oestradiol and progesterone levels, accurate identification of cycle phase is unlikely8,10. There is a clear 
need to develop more accurate methods for cycle verification given this is a significant limitation in 
female specific research.  
The primary aim of this study was to investigate the effectiveness of an individualised three-step method 
of hormonal cycle verification for determination of mid-luteal or high ovarian hormone phase in both 
endogenous and exogenous ovarian cycles in physically-active women. The secondary aim was to 
explore hormonal and demographic characteristics associated with successful or unsuccessful 
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classification of mid-luteal or high hormone phase in both endogenous and exogenous ovarian hormone 
cycles from the three-step method of menstrual cycle verification. 
2. Methods 
Fifty-four recreationally-active women (≥150 min.week-1 of physical activity) who were either long-
term (minimum six months) oral contraceptive users (OC-group; n=28) or experiencing regular natural 
menstrual cycles 25-40 days in length, with no OC use for a minimum of six months prior to study 
inclusion (MC-group; n=26) participated in the study. All experimental procedures were approved by 
the Institutional Medical Human Research Ethics Committee (ethical clearance #2012001438) and 
participants provided written informed consent. 
Participants completed a menstrual cycle diary (adapted from Prior et al.5) for three consecutive cycles 
to determine average cycle length; calculated as the number of days between the onset of consecutive 
menses. The menstrual diary determined approximate follicular and luteal phases and estimated point 
of ovulation11. All participants in the OC-group were taking a monophasic, combined OC, with ethinyl 
oestradiol (20-30 mcg, i.e. low dose) and a second or third generation progestin. The OC-group mapped 
their cycle based on their pill packaging, with day one coinciding with the first withdrawal day (inactive 
pill); if participants reported missing two or more consecutive pills in one cycle, testing was delayed 
until adherence was confirmed. 
Urinary ovulation prediction testing was performed during the experimental cycle to verify cycle phase 
and ovulation in the MC-group and confirm exogenous hormone control in the OC-group. Participants 
were provided a home urine ovulation prediction test for luteinising hormone surge detection 
(Discover® 7-Day Pregnancy Planning kit, Church and Dwight Australia Pty Ltd.; 95% specificity; 99% 
accuracy) and instructed to follow the manufacturer’s directions to perform ovulation prediction testing 
for seven consecutive days during one cycle. Results were confirmed by visual inspection of the test 
strip (participant) and photographic record confirmation (project staff). Two days following the urinary 
luteinising hormone surge, ovulation was assumed to occur, with the mid-luteal phase beginning six to 
eight days following ovulation. An absence of the luteinising hormone surge during the menstrual cycle 
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(MC-group only) indicated absence of ovulation. In this case, testing was delayed by a further cycle 
until a positive urinary ovulation test was experienced. If three consecutive non-ovulatory cycles were 
experienced, participants were excluded from the study.  
Six to 12 days following positive ovulation prediction, participants attended the laboratory on two 
occasions, separated by at least two days. Both sessions occurred at the same time of day to minimise 
diurnal hormone fluctuations9. MC participants attended during the estimated mid-luteal phase, six to 
12 days following ovulation12; OC participants attended in the final two weeks of the consumption 
phase (days 15-28). At each visit, venous blood (12 mL) was sampled from an antecubital vein for later 
serum/plasma hormone analysis. Height and body mass were measured using a stadiometer (Seca, 
Birmingham, UK) and electronic scales (A&D Mercury, Pty Ltd., Thebarton, AUS), respectively. Body 
composition (body mass, lean body mass, fat mass and body fat percentage) was assessed by dual-
energy x-ray absorptiometry (Hologic Discovery W, QDR 4500A, Waltham, Mass., USA). Scans were 
analysed using software (APEX version 3.3) provided by the manufacturer (Hologic, Bedford, Va., 
USA) and according to manufacturer instructions. The coefficient of variation (CV) in our laboratory 
for whole body mass, lean body mass, fat mass and body fat percentage are 0.1%, 0.4%, 1.2% and 
1.2%, respectively.  
Successful verification of mid-luteal phase in the MC-group was defined as a progesterone 
concentration >6 ng.mL-1 13,14. Higher sex-hormone binding globulin concentrations are observed in 
women taking OC compared to women not taking an OC15-17 and was used as a physiological indicator 
of OC compliance in the OC-group16. Free androgen index was calculated  by the method of Vermeulen 
et al.14. Total testosterone and the free androgen index are higher in women who exhibit menstrual 
disturbances17; therefore, these measures were explored in relation to unsuccessful classification of mid-
luteal phase. 
Venous blood was collected into prepared vacuum tubes containing K3EDTA or micronised silica until 
centrifugation. Serum tubes (micronised silica) were allowed to clot at room temperature, and plasma 
tubes (K3EDTA) were stored on ice. After 30 min, samples were centrifuged at 1100 x G for 10 min at 
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4° C. Serum and plasma was removed, placed into separate 0.4 mL aliquots and stored at -80° C until 
analysis. Plasma samples were analysed for oestradiol, progesterone and testosterone, whilst serum 
samples were analysed for sex-hormone binding globulin using a Cobas e411 electrochemilumescence 
immunoassay autoanalyser (Roche Diagnostics, Germany) and manufacturer-recommended Elecsys 
assays. Manufacturer-supplied reagents were used, and instruments were calibrated according to the 
manufacturer’s instructions. The CV’s in our laboratory for oestradiol-II, progesterone, testosterone and 
sex-hormone binding globulin are 3.1%, 5.1%, 4.8% and 3.1%, respectively.    
Data were analysed using Microsoft Excel 2007 and SPSS (version 22.0, SPSS, Inc., Chicago, IL, 
USA). Where data were not normally distributed (assessed by the Shapiro-Wilk test; p<0.05), data were 
log-transformed and re-checked for normality of distribution. Analyses included standard descriptive 
statistics, frequency counts, Pearson’s (rp) and Spearman’s (rs) correlation coefficients and independent 
samples t-tests. Variables that were significantly different between successful and unsuccessful 
classification were placed into unadjusted (univariate) and significant predictors were placed into 
adjusted (multivariate) binary logistic regression models to ascertain the effects of variables on the 
likelihood that participants had luteal phase deficiency. All models were tested for goodness of fit using 
the Hosmer and Lemshow test with significance for fit set at p<0.05.  All tests were two-tailed and 
statistical significance was set at p<0.05. Results are given as mean±SD, unless stated otherwise.  
3. Results   
There were no differences (p>0.05) between OC- and MC-groups for age, body mass index or body 
composition (Table 1). Following serum/plasma hormone analysis, the MC-group was sub-divided into 
‘normal’ (MCNORM; n=18; 70%) and luteal phase deficient (i.e. not meeting minimum progesterone 
concentration criteria for mid-luteal phase; MCLPD; n=8; 30%) groups. MCLPD participants were younger 
(p=0.024), had lower body mass (p=0.048) than MCNORM participants, were shorter than OC participants 
(p=0.042), and had lower fat mass (p=0.002 vs. MCNORM; p=0.022 vs. OC) and body fat % than both 
MCNORM (p=0.005) and OC (p=0.034) participants. The MC-group had longer cycles than the OC-group 
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(p<0.001); MCLPD participants had longer cycles than both MCNORM (p=0.003) and OC (p<0.001) 
participants.  
Two (7.7%) MC participants reported anovulatory cycles, and completed a second cycle of ovulation 
prediction testing prior to serum/plasma hormone sampling. Both participants reported a positive test 
in the second cycle, and did not cluster in either normal or luteal phase deficient groups. Four (14.3%) 
OC participants reported a positive ovulation prediction test (no illness/compliance issues were 
reported) and completed a second cycle of testing; none of these participants reported ovulation in the 
second cycle. Following inclusion in the study and completion of the test cycle, two (7.7%) MC 
participants reported abnormal (late or absent) menstruation in the following cycle. Positive ovulation 
prediction tests in the MC-group occurred 15±2 days after the onset of menstruation (range 10-19 days).  
All OC participants recorded suppressed progestogen concentrations with no differences (p=0.847) 
between Day 1 and Day 2 (Table 2). Plasma progesterone analysis indicated that 18 (70%) MC 
participants met the >6 ng.mL-1 progesterone criterion for mid-luteal phase on one (n=18; 70%) or both 
(n=14; 54%) days and were classified as ‘normal’ (MCNORM). Despite confirming a positive ovulation 
prediction test, eight (30%) participants exhibited progesterone concentrations <6.0 ng.mL-1 on both 
testing days, indicating probable luteal phase deficiency (MCLPD)9,13. When MCLPD participants were 
excluded from analysis, the three-step method was 89% (n=32) successful at determining mid-luteal 
phase and 100% (n=24) successful when testing occurred between days 21-24 of the menstrual cycle 
or seven to ten days following positive testing, indicating higher success than early (days six; n=3/4; 
75%) or late (days 11-12; n=5/8; 62.5%) in the testing period.  
Logistic regression was performed to ascertain the individual effects of age, cycle length, body mass, 
body fat percentage, and fat mass on the likelihood that participants had luteal phase deficiency (Table 
3). Lower age (p=0.041), longer cycle length (p=0.016), lower body fat percentage (p=0.035), and less 
fat mass (p=0.028) were associated with higher likelihood of luteal phase deficiency, and correctly 
classified 80.8%, 84.6%, 84.6% and 88.5% of cases, respectively. When combined into one prediction 
model, age, cycle length and body fat percentage (fat mass was excluded due to its similarity with body 
 9 
fat percentage), the model was statistically significant (X2=27.127; p<0.001) and correctly classified 
96.2% of cases; however, due to the low sample size, no predictors were considered significantly 
predictive within the model (all p>0.05).  
4. Discussion  
The present three-step method for hormone cycle verification was successful in identifying mid-luteal 
menstrual phase in 70% of participants experiencing natural menstrual cycles. In the remaining 30% of 
cases, even though participants reported positive urinary ovulation prediction testing, serum/plasma 
hormone concentrations did not satisfy the criterion for mid-luteal phase. The findings suggest there 
are significant hormonal, body composition and menstrual cycle characteristic differences between 
regularly-menstruating women who exhibit normal luteal phase characteristics and those who exhibit 
luteal phase deficiency. When luteal phase deficient participants were excluded, the method was 90% 
successful, demonstrating the importance of identifying abnormal luteal phase characteristics in 
menstrual cycle verification.   
The three-step method successfully identified low endogenous oestradiol and progesterone hormone 
concentrations in 100% of participants using an OC. However, four (14%) OC participants reported 
ovulation in the first testing cycle, highlighting the importance of utilising ovulation testing in research 
studies involving OC users to confirm anovulation. Previous research has not verified OC use with a 
biomarker, likely due to the assumption that the active hormone pill has been correctly consumed for a 
sufficient number of consecutive days to ensure exogenous hormone control of the phases18,19. In the 
present study, sex-hormone binding globulin concentrations were three-fold higher in the OC-group 
compared to the MC-group. All OC participants exhibited sex-hormone binding globulin concentrations 
above physiologically normal concentrations for naturally-menstruating women (approximately three 
times higher; p<0.001), verifying 100% OC adherence. This novel biomarker of OC adherence has 
potential application in future research where OC use should be biochemically confirmed. 
An important finding of the present study are the significant hormonal, body composition and 
demographic differences between participants who were successfully classified in mid-luteal phase 
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compared to those who displayed apparent luteal phase deficiency. Luteal phase deficiency is defined 
as either reduced progesterone concentrations or shortening of the luteal phase (<10 days), characterised 
by a minimal progesterone surge9, 20,21. Previously, Wideman et al.9 demonstrated that anovulatory and 
luteal phase deficient women had lower body mass index than ovulatory women; reflective of the 
present findings where MCLPD participants had lower body fat indices. Additionally, previous research 
suggests women with higher physical activity levels and/or lower caloric intake are likely to show more 
variable sex hormone concentrations across menstrual cycles22. Physically-active women also have 
increased likelihood of anovulation and luteal phase deficiency, which have no perceptible 
symptoms23,24, are not reflected in bleeding patterns20,21, and are not identified through questionnaires25. 
In physically-active women, the prevalence of luteal phase deficiency has been reported as high as 
79%20,21. Therefore, as participants in the present study were all recreationally physically-active, the 
30% incidence of luteal phase deficiency is not surprising and may indeed be lower than previously 
reported. It is also important to note that self-reported physical activity was not different between 
MCNORM and MCLPD participants, therefore the difference between groups may be more related to 
energy balance. Biochemically, participants exhibiting characteristics of luteal phase deficiency had a 
higher free androgen index, but similar total testosterone concentrations compared to regularly-
menstruating women. This could potentially allow identification of luteal phase deficiency through free 
androgen measurement, which does not require stringent cycle phase verification and could be 
completed at any time point, regardless of menstrual cycle phase26. 
When combined in a multivariate binary logistic regression age, cycle length and body fat percentage 
correctly classified 96.2% of cases, despite none of the predictors statistically significantly contributing 
to the outcome. This is likely due to the low numbers involved in the study; a larger sample size may 
have increased the ability to determine significant contributions of each of the variables. Despite this, 
our finding demonstrates that simply-measured characteristics such as age, cycle length and body 
composition may have the potential to identify luteal phase deficient phases cases. Luteal phase 
deficiency has no perceptible symptoms23,24 and as such, may have been implicated in the incorrect 
classification of mid-luteal phase in previous research. Assessment of these measures prior to study 
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inclusion may assist in predicting participants who may not exhibit normal luteal phase characteristics, 
despite exhibiting normal ovulatory characteristics. The ability to differentiate individuals with luteal 
phase deficiency would enable development of stricter exclusion criteria for research studies that 
require female participants with normal luteal phase characteristics, within sports and exercise science 
and medicine, fertility, and intervention studies.  
We recognise several limitations of the present study. Firstly, while urinary ovulation prediction  has 
been shown to be superior to other methods of ovulation prediction7,27,28, it remains a predictive test and 
no direct measure of ovulation was employed. Urinary ovulation prediction is limited by subjective 
interpretation of the test result and accuracy is reduced in populations where ovulatory disturbances are 
prevalent30. The predictive methods employed were minimally invasive and cost-effective, and 
therefore more applicable in practical research environments. Secondly, menstrual dysfunction is less 
likely to occur when women have adequate caloric intake23 and when there is positive energy 
balance20,29. Measurement of caloric intake and energy expenditure within this study may have 
enhanced identification of luteal phase deficiency, especially considering self-report physical activity 
was not different among groups. Thirdly, we acknowledge the potential limitations of clinical diagnostic 
auto-immunoassay techniques compared to traditional mass spectrometry techniques for steroid 
hormone analysis. Detection sensitivity limits were too high for OC-group oestradiol measures, and 
further investigation should consider mass spectrometry as a potentially more sensitive technique. 
Finally, the testing window was possibly too wide, with the majority of incorrect classifications 
occurring early and late (Day six and 12 following the positive ovulation prediction test) coinciding 
with Days 19 and 27 following the onset of menstruation, respectively. With insights from the present 
findings, we recommended testing between days seven and nine following the positive ovulation 
prediction test (days 20-22 following the onset of menstruation), where 100% of trials in participants 
with normal luteal function were successfully classified.  
5. Conclusion 
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Our findings suggest the three-step method comprising menstrual cycle mapping, home urinary 
ovulation prediction testing and serum/plasma hormone measurement is effective at verifying hormone 
status in women using OC 100% of the time, and 70% of the time in naturally-menstruating women. 
Once luteal phase deficient participants were excluded the method was successful 90% of the time in 
normally-menstruating women. If tight control of ovarian hormones is required within a study design, 
women taking an OC may be more suitable participants than naturally-menstruating women; but 
ovulation testing should still be included. Given the impracticalities surrounding daily serum/plasma 
hormone measures or direct measures of ovulation, the use of the three-step method for hormone cycle 
verification is a more cost-effective and less invasive method for verifying ovarian hormone status in 
the majority of women. Consideration of age, body composition (specifically indices of fat mass) and 
additional hormone characteristics, including free androgen index and sex-hormone binding globulin 
could inform more accurate and cost-effective methods for successfully categorising menstrual phase 
in physically-active women.  
6. Practical implications  
 Step-wise menstrual cycle mapping, urinary ovulation prediction testing, and serum/plasma 
hormone verification are an effective combination for accurate verification of mid-luteal menstrual 
phase. Identification of mid-luteal phase is essential to determine the influence of ovarian hormone 
concentrations on both acute and chronic physiological and performance adaptations in sport and 
exercise science and medicine.  
 We recommend testing seven to nine days following positive ovulation prediction testing, or 20-
22 days following onset of menstruation, where we determined the highest likelihood of correct 
mid-luteal phase classification.  
 Screening of potential luteal phase deficient women should consider age, cycle length and body 
fat indices.  
 Identification of biomarkers with minimal cyclic fluctuations, including sex-hormone binding 
globulin (for OC use), and free androgen index (for potential luteal phase deficiency) will enhance 
identification of menstrual characteristics/disturbances.  
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 The ability to identify individuals with luteal phase deficiency enables development of stricter 
exclusion criteria for research studies that require female participants with normal menstrual 
characteristics within sports and exercise science and medicine.  
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Table 1: Participant characteristics  
MCALL: menstrual cycle group; MCNORM: menstrual cycle participants meeting normal mid-luteal phase criteria; MCLPD: menstrual cycle participants exhibiting luteal phase 
deficiency; NA: not applicable. Parametric data are presented as mean±SD (95%CI); non-parametric data are presented as median [IQR] (95%CI).  
* p<0.05 vs. MCNORM; # p<0.05 vs. OC   
 
                                                 Oral contraceptive group (OC; n=28) Menstrual cycle group (MC; n=26)  
  MCALL (n=26) MCNORM n=18 MCLPD n=8 
Age (years) 25±5 (23-27) 26±5 (24-28) 27±5 (25-30) 23±3 (20-25)* 
Body mass (kg) 65±7 (63-68) 65±9 (61-68) 67±9 (63-72) 60±7 (54-66)* 
Stature (cm) 169±5 (167-172) 168±7 (165-171) 170±7 (166-173) 165±6 (160-170)# 
Body mass index (kg.m-2) 22.6±1.9 (22.0-23.5) 22.9±2.1 (22.0-23.7) 23.3±2.1 (22.3-24.4) 21.2±2.1 (20.2-23.7) 
Bone mineral content (kg) 1.7±0.3 (1.6-1.8)  1.8±0.3 (1.6-1.9) 1.8±0.3 (1.6-1.9) 1.8±0.3 (1.5-2.0) 
Fat mass (kg) 19.7±4.2 (18.5-21.8) 19.8±5.0 (17.6-21.7) 21.7±4.2 (19.6-23.8) 15.7±4.0 (12.4-19.0)*# 
Lean body mass (kg) 38.2±3.9 (36.6-39.8) 38.1±5.6 (35.5-40.3) 38.5±6.1 (35.5-41.6) 37.1±4.3 (33.5-40.6) 
Body fat (%) 32.1±4.5 (30.9-34.4) 32.3±5.3 (30.0-34.6) 34.2±4.6 (31.9-36.4) 28.1±4.7 (24.2-32.0)*# 
Cycle length (days) 28±0 (28-28) 31±4 (30-33)# 30±2 (29-31) 34±5 (31-38)*# 
Positive ovulation test (day) NA 15±2 (14-16) 15±2 (14-16) 15±3 (12-17) 
Test day 1 (day)  17±4 (16-19) 22±2 (21-23)# 22±2 (21-23)# 22±3 (19-24)# 
Test day 2 (day) 20±4 (18-22) 25±2 (24-25)# 25±2 (24-26)# 24±3 (22-26)# 
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Table 2: Participant hormone characteristics 
MCNORM: menstrual cycle participants meeting normal progesterone characteristics for mid-luteal phase criteria; MCLPD: menstrual cycle participants exhibiting 
progesterone characteristics for luteal phase deficiency; SHBG: sex-hormone binding globulin. Data are presented as mean±SD (95%CI).  
# p<0.05 vs. OC; * p<0.05 vs. MCNORM  
 
Oral contraceptive group (OC; n=28)             Menstrual cycle group (MC; n=26) 
   MCNORM (n=18)  MCLPD (n=8) 
Oestradiol (pg.mL-1) Day1 10.3±9.3 (6.7-14.4) 137.6±74.5 (105.6-169.9)# 144.2±53.7 (117.5-170.9)# 120.5±116.3 (12.9-228.1)#* 
Day 2 9.0±5.2 (7.1-11.3) 114.6±50.4 (93.3-135.9)# 132.4±32.8 (116.1-148.7)# 68.7±51.8 (25.4-112.1)#* 
Progestogen (ng.mL-1) Day 1 0.6±0.3 (0.5-0.7) 10.4±8.1 (7.0-13.8)# 14.2±5.9 (11.3-17.2)# 0.9±0.5 (0.4-1.3)#* 
Day 2 0.6±0.3 (0.5-0.7) 6.9±5.5 (5.0-9.6)# 9.6±4.4 (7.5-11.8)# 0.9±0.3 (0.6-1.1)* 
Total testosterone  (ng.mL-1) Day 1 0.2± 0.1 (0.2-0.3) 0.2±0.2 (0.1-0.3) 0.2±0.2 (0.1-0.3) 0.3±0.2 (0.1-0.5) 
Day 2 0.2±0.1 (0.1-0.2) 0.2±0.2 (0.1-0.3) 0.2±0.2 (0.1-0.3) 0.3±0.2 (0.1-0.5)# 
SHBG (pg.mL-1) Day 1 196.2±89.4 (160.1-232.3) 64.6±35.3 (51.4-81.1)#  64.2±29.9 (49.3-79.0)# 65.7±49.6 (19.9-111.6)# 
Day 2 196.3±93.1 (160.7-236.6) 64.1±30.4 (52.8-78.7)# 62.7±26.6 (49.5-75.9)# 67.2±39.5 (34.2-100.3)# 
Free androgen index Day 1 0.2± 0.1 (0.1-0.2) 0.5±0.6 (0.2-0.8)# 0.3±0.3 (0.2-0.5)# 0.8±1.1 (0.0-1.8)#* 
Day 2 0.1± 0.1 (0.1-0.2) 0.4±0.6 (0.2-0.7)# 0.3±0.4 (0.1-0.5)# 0.7±0.9 (0.0-1.4)#  
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Table 3: Binary logistic regression examining the prediction of luteal phase deficiency in regularly menstruating women.  
NA: not applicable  
 
   
 Unadjusted Adjusted 
 Odds ratio 95% confidence interval p-value Odds ratio 95% confidence interval  p-value 
Age (years) 0.762 0.587-0.989 0.041 0.175 0.001-27.560 0.500 
Cycle length (days)  1.695 1.104-2.602 0.016 0.391 0.073-79.321 0.391 
Body mass (kg) 0.869 0.749-1.009 0.065 NA NA NA 
Fat mass (kg) 0.999 0.999-1.000 0.028 NA NA NA 
Body fat (%) 0.444 0.209-0.943 0.035 0.385 0.003-9.880 0.385 
